Surfactant protein D as a novel therapy for periventricular leukomalacia: is it the missing piece of the puzzle?

Defne Engür1, Abdullah Kumral

  • 1Neonatology Department, Adnan Menderes University, Aydin, Turkey.

ACS Chemical Neuroscience
|December 22, 2012
PubMed

Insights

Surfactant protein D (spD) may prevent periventricular leukomalacia (PVL) by suppressing inflammation and protecting developing brain cells. This agent targets pathways involving Toll-like receptors (TLRs) and lipopolysaccharide (LPS).

Area of Science:

  • Neuroscience
  • Immunology
  • Neonatal Research

Background:

  • Periventricular leukomalacia (PVL) involves microglia activation and subsequent death of premyelinating oligodendrocytes.
  • Toll-like receptor (TLR) 4 is implicated in lipopolysaccharide (LPS)-induced oligodendrocyte injury in the central nervous system (CNS).

Purpose of the Study:

  • To investigate surfactant protein D (spD) as a potential therapeutic agent against PVL.
  • To evaluate spD's ability to counteract inflammatory pathways in the premature brain.

Main Methods:

  • The study focuses on the interaction of spD with TLR 2, TLR 4, and CD14.
  • Investigating the role of TLRs in inflammatory insults leading to PVL.

Main Results:

  • Surfactant protein D (spD) shows potential in binding to TLR 2, TLR 4, and CD14.
  • spD may counteract inflammatory pathways implicated in PVL.

Conclusions:

  • Supplementing surfactant treatment with spD could be crucial for preventing PVL.
  • spD may protect vulnerable premature brains by suppressing inflammation and preventing pre-OL damage via TLRs.